Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Acinetobacter baumannii

ABSTRACT: Molecular and clinical epidemiology of carbapenem resistant Acinetobacter baumannii in Oceania

PROVIDER: PRJNA1007430 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26357333_1.fastq.gz	Fastqsanger.gz
	SRR26357333_2.fastq.gz	Fastqsanger.gz
	SRR26357334_1.fastq.gz	Fastqsanger.gz
	SRR26357334_2.fastq.gz	Fastqsanger.gz
	SRR26357335_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 28

Similar Datasets

Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii

Project description:Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii

| PRJEB27899 | ENA

Acinetobacter baumannii response to cefiderocol challenge in human urine

Project description:Cefiderocol (CFDC) is a novel chlorocatechol-substituted siderophore approved to treat complicated urinary tract infections and for hospital-acquired and ventilator-acquired pneumonia. In previous work, human fluids, were shown to increase the minimum inhibitory concentration (MICs) of Acinetobacter baumannii against CFDC and reduce the expression of genes related to iron uptake systems, which could explain the need for higher concentrations of CFDC to exert inhibitory action. Herein, we analyzed the impact of human urine (HU), which contains low albumin concentrations, on the expression of iron-uptake related genes and MIC values of two carbapenem-resistant A. baumannii. Levels of resistance to CFDC were not modified by HU in strain AMA40 but were reduced in the case of strain AB5075. Testing other carbapenem-resistant A. baumannii isolates showed that the CFDC MICs were unmodified or reduced in the presence of HU. The expression of piuA, pirA, bauA, and bfnH determined by qRT-PCR was enhanced in both strains when HU was present in the culture medium. All four tested genes are involved in recognizing ferric siderophore complexes or internalization into the cell’s cytosol. In contrast, the effect of HU on genes associated with resistance to β-lactams, antibiotics commonly used to treat urinary tract infections caused by A. baumannii, was variable; the transcriptional analysis of pbp1, pbp3, blaOXA-51-like, blaADC, and blaNDM-1 showed significant variation. In summary, HU, probably due to the albumin and free iron content, does not adversely impact or slightly improves the activity of CFDC when tested against A. baumannii in urine in contrast to other human bodily fluids.

2022-06-01 | GSE201259 | GEO

Project description:Molecular and clinical epidemiology of carbapenem resistant Acinetobacter baumannii ST2 in Oceania

| PRJNA1005029 | ENA

Transcription profiling of Acinetobacter baumannii multi-drug resistant strain and a susceptible reference strain - Abefflux

Project description:Transcriptomic comparison of a multidrug resistant Acinetobacter baumannii strain and a susceptible reference strain.

2009-11-20 | E-MEXP-2254 | biostudies-arrayexpress

Acinetobacter baumannii

Project description:Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii strains in Belgian acute-care hospitals

| PRJNA734485 | ENA

Generation of synthetic Acinetobacter baumannii specific nanobodies

Project description:The bacterial pathogen, Acinetobacter baumannii, is a leading cause of drug-resistant infections. Here, we investigated the potential of developing nanobodies that specifically recognize A. baumannii over other Gram-negative bacteria. Through generation and panning of a synthetic nanobody library, we identified several potential lead candidates. We demonstrate how incorporation of next generation sequencing analysis can aid in selection of lead candidates for further characterization. Using monoclonal phage display, we validated the binding of several lead nanobodies to A. baumannii. Subsequent purification and biochemical characterization revealed one particularly robust nanobody that broadly and specifically bound A. baumannii compared to other common drug resistant pathogens. These findings support the potentially for nanobodies to selectively target A. baumannii and the identification of lead candidates for possible future diagnostic and therapeutic development.

2023-06-21 | GSE202972 | GEO

Transcriptional changes in response to OXA-23 overexpression in Acinetobacter baumannii ATCC 17978

Project description:Purpose: The goal of this study was to elucidate the collateral effects associated with OXA-23 overexpression on the Acinetobacter baumannii global transcriptome. Results: Besides the 99.73-fold increase in blaOXA-23 transcript upon IPTG induction, no other transcripts showed more than a 2-fold change compared to the wildtype control. This suggests that OXA-23 over expression to levels similarly observed in multi drug resistant A. baumannii clinical isolates does not effect the transcriptome.

2021-11-15 | GSE185203 | GEO

Acinetobacter baumannii

Project description:Carbapenem resistant Acinetobacter baumannii

| PRJNA530638 | ENA

Acinetobacter baumannii

Project description:carbapenem-resistant Acinetobacter baumannii

| PRJNA1083246 | ENA

Acinetobacter baumannii

Project description:Carbapenem resistant Acinetobacter baumannii

| PRJNA494506 | ENA